Albumin concentration significantly impacts on free teicoplanin plasma concentrations in non-critically ill patients with chronic bone sepsis.

[1]  J. Rello,et al.  Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: lessons from the DALI Study. , 2014, International journal of antimicrobial agents.

[2]  M. Roberts,et al.  Altered Pharmacokinetics of Piperacillin in Febrile Neutropenic Patients with Hematological Malignancy , 2014, Antimicrobial Agents and Chemotherapy.

[3]  M. Doi,et al.  Plasma exposure of free linezolid and its ratio to minimum inhibitory concentration varies in critically ill patients. , 2013, International journal of antimicrobial agents.

[4]  J. Roberts,et al.  Protein Binding of β-Lactam Antibiotics in Critically Ill Patients: Can We Successfully Predict Unbound Concentrations? , 2013, Antimicrobial Agents and Chemotherapy.

[5]  J. Rello,et al.  The Effects of Hypoalbuminaemia on Optimizing Antibacterial Dosing in Critically Ill Patients , 2011, Clinical pharmacokinetics.

[6]  J. Rello,et al.  Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics. , 2010, The Journal of antimicrobial chemotherapy.

[7]  R. Seaton,et al.  Development of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) programme. , 2009, The Journal of antimicrobial chemotherapy.

[8]  A. Brink,et al.  Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis. , 2009, International journal of antimicrobial agents.

[9]  A. Brink,et al.  Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsis. , 2008, International journal of antimicrobial agents.

[10]  B. Bourgeois,et al.  Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies , 2008, Epilepsia.

[11]  N. Goto,et al.  Variability in Teicoplanin Protein Binding and Its Prediction Using Serum Albumin Concentrations , 2007, Therapeutic drug monitoring.

[12]  D. Soy,et al.  Teicoplanin Population Pharmacokinetic Analysis in Hospitalized Patients , 2006, Therapeutic drug monitoring.

[13]  P. Viale,et al.  The effect of multifactorial, multidisciplinary educational interventions on appropriate use of teicoplanin. , 2006, International journal of antimicrobial agents.

[14]  B. Debaene,et al.  Steady-state trough serum and epithelial lining fluid concentrations of teicoplanin 12 mg/kg per day in patients with ventilator-associated pneumonia , 2006, Intensive Care Medicine.

[15]  R. Greenberg.  Treatment of bone, joint, and vascular-access-associated gram-positive bacterial infections with teicoplanin , 1990, Antimicrobial Agents and Chemotherapy.